Drug news
Bayer returns rights of ATX 101 to Kythera a treatment for submental fat
Bayer HealthCare and Kythera announced that Bayer will sell back to Kythera commercial rights to ATX-101 (sodium deoxycholate) outside of the U.S. and Canada. In 2010, Bayer licensed these rights from Kythera. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid currently in Phase III development for the reduction of submental fat (double chin).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.